

Switch from Enfuvirtide to Raltegravir  
**CHEER Trial**

# Switch from Enfuvirtide to Raltegravir

## CHEER: Study Design

### Study Design: CHEER

- **Background:** Prospective, nonrandomized, open-label, historical control study evaluating switch from enfuvirtide to raltegravir in virologically suppressed adults with HIV.
- **Inclusion Criteria (n =52)**
  - Age  $\geq 18$  years
  - HIV RNA  $< 50$  copies/mL (by PCR) or  $< 75$  copies/mL (by bDNA) for  $\geq 6$  months
  - No prior treatment with integrase inhibitors
- **Treatment Arm**
  - Raltegravir + background antiretroviral regimen (patients served as own controls)


**Raltegravir 400 mg BID +  
background ART**

(n = 52)

# Switch from Enfuvirtide to Raltegravir

## CHEER: Results

Week 24: Virologic Response (Non-completer=Failure, ITT Analysis)



# Switch from Enfuvirtide to Raltegravir

## CHEER: Conclusions

**Conclusions:** “In treatment-experienced patients on a stable virologically suppressive enfuvirtide-containing regimen, raltegravir can safely be substituted for enfuvirtide.”

# Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

*The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.*

